This study is designed to evaluate the efficacy of AMG 714 for the treatment of adult participants with vitiligo.
Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)
The primary objective of this trial is to determine the efficacy of interleukin-15 (IL-15) inhibition with AMG 714 at inducing facial repigmentation in vitiligo. The secondary objectives are to: -Evaluate the safety and tolerability of AMG 714 in vitiligo- -Determine the efficacy of IL-15 inhibition with AMG 714 at inducing total body skin repigmentation in vitiligo- - Assess the durability of the skin repigmentation achieved by AMG 714 in vitiligo, and - Evaluate the efficacy of AMG 714 followed by narrow band UVB (nbUVB) phototherapy.